Tianjin Pharma Announces Joint Venture Extension

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has announced the extension of its associated company’s operating period to facilitate future planning and shareholder discussions. The Sino-American joint venture, TSKF, in which they hold a 25% stake, will now continue operations until 30 June 2025, with all necessary industrial and commercial registration changes completed. This extension is not expected to impact the company’s production and operations.

For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.